Blood. 2011 Aug 19. [Epub ahead of print]
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study.
Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A.
SourceDepartment of Leukemia, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States;
Abstract
Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with CLL (chronic lymphocytic leukemia) refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (>5cm) lymph nodes (BF-ref). To potentially gain insight into outcomes in patients previously treated with or refractory to rituximab, we performed an ad hoc retrospective analysis in the final 96 FA-ref and 111 BF-ref patients. There were 117 patients previously treated with rituximab (98 rituximab-refractory); 89 patients were rituximab-naïve. For rituximab-treated, rituximab-refractory, and rituximab-naïve patients, ORR was 43%, 44%, and 53%; mPFS was 5.3, 5.5, and 5.6 months; and mOS was 15.5, 15.5, and 20.2 months. There were no significant differences in ofatumumab-related infusion reactions, or hematologic or infectious AEs between subgroups. In summary, ofatumumab monotherapy was effective and well tolerated in patients with fludarabine-refractory CLL, including in patients with previous rituximab exposure (www.ClinicalTrials.gov: NCT00349349).
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study.
Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A.
SourceDepartment of Leukemia, Division of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States;
Abstract
Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with CLL (chronic lymphocytic leukemia) refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (>5cm) lymph nodes (BF-ref). To potentially gain insight into outcomes in patients previously treated with or refractory to rituximab, we performed an ad hoc retrospective analysis in the final 96 FA-ref and 111 BF-ref patients. There were 117 patients previously treated with rituximab (98 rituximab-refractory); 89 patients were rituximab-naïve. For rituximab-treated, rituximab-refractory, and rituximab-naïve patients, ORR was 43%, 44%, and 53%; mPFS was 5.3, 5.5, and 5.6 months; and mOS was 15.5, 15.5, and 20.2 months. There were no significant differences in ofatumumab-related infusion reactions, or hematologic or infectious AEs between subgroups. In summary, ofatumumab monotherapy was effective and well tolerated in patients with fludarabine-refractory CLL, including in patients with previous rituximab exposure (www.ClinicalTrials.gov: NCT00349349).
30/8 2011 18:00 1
45825 Det er denne type artikler der forhåbentligtvis er med til at overbevise klinikkerne om at de skal prøve arzerra offlabel.
30/8 2011 19:36 MadsSkjern 045828 Superfedt at du linker til alle de nye ofatumumab artikler - også i Genmab-gruppen.
Snebolden ruller. Jeg får lyst til at trykke på købsknappen igen, men må hellere holde snitterne i lommen :o)
Snebolden ruller. Jeg får lyst til at trykke på købsknappen igen, men må hellere holde snitterne i lommen :o)
